Abstract: The present application relates to the field of inflammatory diseases, particularly to inflammatory diseases characterized by an M1 macrophage response, even more particularly to sepsis and to Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.

Abstract: A computer-implemented method and related device are disclosed for determining a plurality of operating scenarios of an energy system. The method comprises obtaining a plurality of performance measures of the energy system as a function of time corresponding to a plurality of sets of values of input variables. The method comprises clustering the plurality of sets of values of the input variables and the performance measures associated therewith into groups and defining a descriptor for each of the groups. The method also comprises outputting the descriptors of the groups for use in an online prediction or offline estimation of the energy system.

Abstract: The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.

Abstract: The present invention provides an oral care composition comprising a carboxylic acid of the formula (I) wherein: R1 is H, or is a substituted or unsubstituted alkyl group; and R2 is H, OH, or NH2; for use in: (a) selectively promoting, in an oral cavity: growth, metabolic activity or colonization of bacteria that have beneficial effects on oral health, relative to growth, metabolic activity or colonization of pathogenic oral bacteria; (b) selectively promoting, in an oral cavity, biofilm formation by bacteria that have beneficial effects on oral health, relative to biofilm formation by pathogenic oral bacteria; or (c) maintaining and/or re-establishing a healthy oral microflora.

Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: A process for preparing cyclic esters by means of a transesterification reaction in the gas phase, comprises the steps of: (i) vaporizing a liquid solution of alpha-hydroxy esters, (ii) passing the ester vapors through a reaction zone containing a solid catalyst and (iii) recovering the cyclic esters from the gaseous product stream; and wherein the solid catalyst comprises at least one metal of titanium (Ti) and Zirconium (Zr), and a SiO2 support, and wherein said metal is chemically bound to the SiO2 support through M-O—Si chemical bonds.

Abstract: The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.

Abstract: Disclosed is a biomedical device being introduced by a hollow tube having a longitudinal axis in a subject in a minimally invasive surgery procedure for watertight sealing of an opening including at least two assemblies, each assembly including one flap connected to one arm, the arm having an longitudinal axis; the assemblies including a delivery configuration, a deployed configuration, and a sealed configuration and outwards deployment unit for switching from the delivery configuration to the deployed configuration and inwards deployment unit for switching from the deployed configuration to the sealed configuration. Also disclosed is a kit of parts including an outer hollow tube, an inner hollow tube, and a related biomedical device.

Abstract: The application relates to methods of curing retroviral infections, i.e. ensuring remission of retroviral infections, more particularly HIV infections, by administering a compound which is capable of binding to the LEDGF/p75 binding pocket of HIV-integrase and inhibiting LEDGF/p75-IN protein-protein interaction. The application further relates to the use of LEDGINs in retroviral gene therapy.

Abstract: Example embodiments relate to selective deposition for interdigitated patterns in solar cells. One embodiment includes a method for creating an interdigitated pattern for a solar cell. The method includes providing a substrate of the solar cell. A surface of the substrate includes one or more exposed regions and one or more regions covered by a patterned first passivation layer stack protected by a hard mask. The method also includes selectively depositing a second passivation layer stack that includes at least a first layer of amorphous silicon (a-Si) on the one or more exposed regions such that the first passivation layer stack and the second passivation layer stack form the interdigitated pattern. Selectively depositing the second passivation layer stack includes adding a sublayer of the first layer on the hard mask, etching the added sublayer on the hard mask, and cleaning a surface of the remaining added sublayer.

Abstract: A method for estimating one or more of the following quantities from an electromechanical machine and/or component, the method comprising the creation of a photorealistic numerical model of the electromechanical machine or parts of it, a measurements step for combining outputs of physical sensors of which at least one is an imaging device for visualizing the external surface of the physical electromechanical machine in at least one 2-dimensional image, an estimation step combining the photorealistic numerical model and measurement step to provide an estimate of desired electromechanical quantities, wherein the estimation step is based at least on the usage of a similarity metric between the (at least one) two dimensional image of the electromechanical machine or parts of it and the images generated by the photorealistic numerical model.

Abstract: The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.

Abstract: The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.

Abstract: An intensified continuous process for synthesizing zeolite crystals is described, said process comprising a continuous supply of a continuously prepared gel, said gel then being continuously crystallized, said process comprising at least one application of ultrasound.

Abstract: The disclosed technology relates to electrode layers of ion insertion type batteries and to electrode layer materials, wherein the electrode layer materials have a good electronic conductivity and a good ion conductivity, and wherein the electrode layers offer a good rate performance and a high storage capacity. The disclosed technology further relates to ion insertion type battery cells and batteries including such electrode layers, e.g., as an anode. The disclosed technology further relates to methods of forming such electrode layers and to methods for fabricating ion insertion type battery cells and batteries. The electrode layers according to the disclosed technology comprise titanium oxide comprising chlorine and may be deposited by atomic layer deposition at temperatures lower than 150° C.

Abstract: A method for manufacturing of a waveguide for guiding an electro-magnetic wave comprising: forming a first waveguide layer, a sacrificial layer and a protection layer on a first wafer, patterning to define a pattern of a first waveguide part and a supporting structure in the first waveguide layer; exposing the sacrificial layer on the first waveguide part while the protection layer still covers the sacrificial layer on the supporting structure; removing the sacrificial layer on the first waveguide part; removing the protection layer; bonding a second wafer to the sacrificial layer of the first wafer such that a second waveguide part is supported by the supporting structure and a gap corresponding to the thickness of the sacrificial layer is formed between the first and second waveguide parts.

Abstract: A method for forming on a substrate a cross-linked layer for directing the self-assembly of a self-assembling material is provided. The method including: (a) providing a structure having the substrate; (b) providing on the substrate a layer of a photo- and thermally cross-linkable substance which, when crosslinked, is suitable for directing the self-assembly of a self-assembling material; (d) photocrosslinking the cross-linkable substance partially; and (d) cross-linking the substance further thermally, thereby forming the cross-linked layer.

Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.

Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.